Document Detail


Accuracy of 18F fluorodeoxyglucose positron emission tomography/computed tomography in staging of pediatric sarcomas.
MedLine Citation:
PMID:  17805034     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The present study was conducted to clarify the diagnostic accuracy of 18F-fluoro-2-deoxy-D-glucose (18FDG) positron emission tomography (PET)/computed tomography (CT) in the staging in pediatric sarcomas. Fifty pediatric patients with histologically proven sarcomas who underwent 18FDG PET/CT before treatment were evaluated retrospectively for the detection of nodal and distant metastases. Diagnostic accuracy of 18FDG PET/CT in detecting nodal and distant metastases was compared with that of 18FDG PET and conventional imaging (CI). The images were reviewed and a diagnostic consensus was reached by 3 observers. REFERENCE standard was histologic examination in 15 patients and confirmation of an obvious progression in size of the lesions on follow-up examinations. Nodal metastasis was correctly assessed in 48 patients (96%) with PET/CT, in contrast to 43 patients (86%) with PET, and 46 patients (92%) with CI. Diagnostic accuracies of nodal metastasis in 3 modalities were similar. Using PET/CT, distant metastasis was correctly assigned in 43 patients (86%), whereas interpretation based on PET alone or CI revealed distant metastasis in 33 patients (66%) and 35 patients (70%), respectively. Diagnostic accuracy of distant metastasis with PET/CT was significantly higher than that of PET (P=0.002) or CI (P=0.008). False negative results regarding distant metastasis by PET/CT in 7 patients (14%) were caused by subcentimetric lesions (n=4), bone marrow lesion (n=2), and soft tissue lesions (n=1). PET/CT is more accurate and probably more cost-effective than PET alone or CI regarding distant metastasis in pediatric sarcomas.
Authors:
Ukihide Tateishi; Ako Hosono; Atsushi Makimoto; Aine Sakurada; Takashi Terauchi; Yasuaki Arai; Yutaka Imai; Euishin Edmund Kim
Related Documents :
19585114 - Efficacy of 18f-fdg pet/ct in the evaluation of patients with recurrent cervical carcin...
17631554 - Diagnostic and prognostic value of 18f-fdg pet/ct for patients with suspected recurrenc...
6659204 - Lymphography and computed tomography in staging nonseminomatous testicular cancer: limi...
10707924 - Values and limitations of 18f-fluorodeoxyglucose-positron-emission tomography with preo...
21415864 - The role of 18-fdg positron emission tomography (fdg-pet) in detecting post- radiothera...
18591004 - Isolated involvement of substantia nigra in acute transient parkinsonism: mri and pet o...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of pediatric hematology/oncology     Volume:  29     ISSN:  1077-4114     ISO Abbreviation:  J. Pediatr. Hematol. Oncol.     Publication Date:  2007 Sep 
Date Detail:
Created Date:  2007-09-06     Completed Date:  2007-11-01     Revised Date:  2011-10-06    
Medline Journal Info:
Nlm Unique ID:  9505928     Medline TA:  J Pediatr Hematol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  608-12     Citation Subset:  IM    
Affiliation:
Division of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, and Department of Radiology, Tokai University School of Medicine, Kanagawa, Japan. utateish@ncc.go.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Child
Child, Preschool
Female
Fluorodeoxyglucose F18 / diagnostic use*
Humans
Male
Neoplasm Staging
Positron-Emission Tomography*
Radiopharmaceuticals / diagnostic use*
Sarcoma / pathology,  radionuclide imaging*
Chemical
Reg. No./Substance:
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A phase 2 feasibility study of sequential, dose intensive chemotherapy to treat progressive low-grad...
Next Document:  Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leuk...